|
|
 Previous Article | Table of Contents | Next Article 
Identification of immature and mature myeloma cells in the bone marrow of
human myelomas
MM Kawano, N Huang, H Harada, Y Harada, A Sakai, H Tanaka, K Iwato and A Kuramoto
Department of Internal Medicine, Research Institute for Nuclear Medicine
and Biology, Hiroshima University, Japan.
With regard to the expression of adhesion molecules, human myeloma cells
freshly isolated from bone marrow were heterogeneous. By two- color
analysis with anti-VLA-5 antibody (PE staining) and FITC-labeled anti-CD38
antibody, we found all myeloma cells located at CD38-strong positive
(CD38++) fraction and identified two subpopulations among these myeloma
cells: CD38++ VLA-5-(VLA-5-) myeloma cells and CD38++ VLA- 5+ (VLA-5+)
myeloma cells. To clarify the biologic character of these two
subpopulations, the morphology, in vitro proliferative activity and in
vitro M-protein secretion were examined in each fraction isolated by the
purification procedure or a cell sorter. Morphologic examination showed
that VLA-5- myeloma cells were mostly immature or plasmablastic and VLA-5+
cells were mature myeloma cells. Furthermore, VLA-5- myeloma cells
proliferated markedly in vitro and responded to interleukin 6 (IL- 6), a
growth factor for myeloma cells, while VLA-5+ myeloma cells showed very low
uptakes of 3H-thymidine and no responses to IL-6 but secreted higher
amounts of M-protein (immunoglobulin) in vitro significantly. Therefore, we
could clarify here heterogeneity of human myeloma cells in the bone marrow
with regard to the expression of VLA- 5, one of integrin adhesion
molecules; VLA-5- myeloma cells were proliferative immature cells and
VLA-5+ cells were mature myeloma cells.
Volume 82,
Issue 2,
pp. 564-570,
07/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Liu, H. Ishikawa, F.-J. Li, Z. Ma, K.-i. Otsuyama, H. Asaoku, S. Abroun, X. Zheng, N. Tsuyama, M. Obata, et al.
Dehydroepiandrosterone Can Inhibit the Proliferation of Myeloma Cells and the Interleukin-6 Production of Bone Marrow Mononuclear Cells from Patients with Myeloma
Cancer Res.,
March 15, 2005;
65(6):
2269 - 2276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kuroda, A. Sakai, Y. Okikawa, S. Munemasa, Y. Katayama, Y. Takimoto, H. Okita, and A. Kimura
The Reason Why High-Dose Melphalan Followed by Autologous Stem-Cell Transplantation Produces Good Response in Multiple Myeloma.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
5201 - 5201.
[Abstract]
|
|
|
|
|
|
|
F. Tanioka, S. Tamashima, S.-i. Shimizu, H. Kobayashi, Y. Kobayashi, and H. Sugimura
A Case of Primary Plasma Cell Leukemia with Hairy-cell Morphology and Lambda-type Bence-Jones Protein. Immunohistochemical and Molecular Analysis
Jpn. J. Clin. Oncol.,
May 1, 2003;
33(5):
232 - 237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J.-F. Rossi, J. Shaughnessy Jr, et al.
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Blood,
July 30, 2002;
100(4):
1113 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ishikawa, N. Tsuyama, S. Abroun, S. Liu, F.-J. Li, O. Taniguchi, and M. M. Kawano
Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6
Blood,
March 15, 2002;
99(6):
2172 - 2178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, J. A. L. Fenton, J. Ashcroft, A. English, R. A. Jones, S. J. Richards, G. Pratt, R. Owen, F. E. Davies, J. A. Child, et al.
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
Blood,
December 1, 2000;
96(12):
3880 - 3886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Mahmoud, R. Fujii, H. Ishikawa, and M. M. Kawano
Enforced CD19 Expression Leads to Growth Inhibition and Reduced Tumorigenicity
Blood,
November 15, 1999;
94(10):
3551 - 3558.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Greipp, T. Leong, J. M. Bennett, J. P. Gaillard, B. Klein, J. A. Stewart, M. M. Oken, N. E. Kay, B. Van Ness, and R. A. Kyle
Plasmablastic Morphology---An Independent Prognostic Factor With Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group
Blood,
April 1, 1998;
91(7):
2501 - 2507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Tsunenari, Y. Koishihara, A. Nakamura, M. Moriya, H. Ohkawa, H. Goto, C. Shimazaki, M. Nakagawa, Y. Ohsugi, T. Kishimoto, et al.
New Xenograft Model of Multiple Myeloma and Efficacy of a Humanized Antibody Against Human Interleukin-6 Receptor
Blood,
September 15, 1997;
90(6):
2437 - 2444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Yi, S. Dabadghao, A. Osterborg, S. Bergenbrant, and G. Holm
Myeloma Bone Marrow Plasma Cells: Evidence for Their Capacity as Antigen-Presenting Cells
Blood,
September 1, 1997;
90(5):
1960 - 1967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urashima, B. P. Chen, S. Chen, G. S. Pinkus, R. T. Bronson, D. A. Dedera, Y. Hoshi, G. Teoh, A. Ogata, S. P. Treon, et al.
The Development of a Model for the Homing of Multiple Myeloma Cells to Human Bone Marrow
Blood,
July 15, 1997;
90(2):
754 - 765.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
